TBMask: Airborne Preventive Measures to Reduce New TB Infections in Household Contacts

Sponsor
Pontificia Universidad Catolica de Chile (Other)
Overall Status
Recruiting
CT.gov ID
NCT04938596
Collaborator
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile (Other), Agencia Nacional de Investigación y Desarrollo, ANID (Other)
400
1
2
34.9
11.5

Study Details

Study Description

Brief Summary

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be set up, to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary health care in a high TB incidence area in Santiago, Chile.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: Respiratory bundle
N/A

Detailed Description

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). In 2018, an estimated 10 million people fell ill with TB worldwide, and more than 1.4 million people died from it, making eradication of this disease in the next decades highly unlikely unless new interventions are discovered. Mycobacterium tuberculosis (Mtb) transmission mainly occurs when patients affected by laryngeal or pulmonary TB cough upon others and the mycobacteria are spread in airborne droplets nuclei smaller than 5 μm that are subsequently inhaled by close contacts. Although chemoprophylaxis once a new TB infection is detected is an effective strategy to reduce the risk of contacts developing active TB, it does not prevent Mtb acquisition; it only reduces the risk of developing active TB once infected. Currently, the large majority of international guidelines recommend strict measures to reduce airborne transmission in hospitalized patients with pulmonary TB, with a minimum of 2 weeks of effective TB therapy to consider a patient no longer infectious and discontinue respiratory isolation in healthcare settings. On the contrary, in the community, no special recommendations regarding protection of household contacts are specified, assuming that most of them are already infected and that the TB index case will stop infecting very quickly under antimicrobial treatment. However, several studies show that median time to sputum Mtb culture conversion under effective treatment takes 5-7 weeks, raising the potential for continued transmission even despite effective treatment. Furthermore, a previous study has shown that in Santiago, Chile, 55% of household contacts of TB cases have no evidence of TB infection at the time of diagnosis of the index case - as categorized by negative latent TB testing - yet under close follow-up, up to 21% of these show new evidence of having acquired the infection based on latent TB test conversion after 12 weeks of follow-up. The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be done to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary care in a high TB incidence area in Santiago. The respiratory bundle in the intervention arm will be implemented as soon as a new pulmonary TB case is diagnosed, will last 2 weeks and, will include: (a) provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, (b) recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others, (c) promotion of strategies to improve house ventilation; and (d) education about TB transmission. The investigators expect to show that this trial is feasible to proceed with a larger, definitive cluster randomized controlled trial that will evaluate the intervention effectiveness in reducing the incidence of new TB infections in household contacts. The results of this study will help to answer a critical research gap in TB infection control and prevention and, it will provide a key contribution to future policies regarding TB control and elimination worldwide. Furthermore, in the new global context of rising infectious agents of pandemic risk, this work may have an additional potential relevance with respect to the use, acceptability and transmission prevention potential of a respiratory bundle in the household setting regarding other respiratory pathogens such as SARS-Cov-2.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Pre-post controlled study. Two different health care areas of Santiago (and their corresponding TB clinics) will be allocated to control or intervention arm; after a baseline pre-intervention period.Pre-post controlled study. Two different health care areas of Santiago (and their corresponding TB clinics) will be allocated to control or intervention arm; after a baseline pre-intervention period.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Strengthening of Airborne Preventive Measures Inside Households of Pulmonary TB Cases as a Tool to Reduce New Infections in Close Contacts. A Pilot, Controlled, Pre-post Study.
Actual Study Start Date :
Oct 4, 2021
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Respiratory Bundle Group

The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.

Combination Product: Respiratory bundle
Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks Promotion of strategies to improve house ventilation during 2 weeks Provision of a TB leaflet and nurse education about TB transmission.

No Intervention: Standard of care

Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.

Outcome Measures

Primary Outcome Measures

  1. Participation rate [2 weeks]

    To document the proportion of TB cases and household contacts who agree to participate as measured by enrollment.

  2. Study compliance [2 weeks]

    To document participants compliance with the respiratory bundle as measured by a previously validated adherence questionnaire.

  3. Completion rate [12 weeks]

    The number of participants assessable at end of follow-up.

  4. Acceptability of the intervention [12 weeks]

    Focus group evaluation (participants and TB nurses perspectives, qualitative outcome).

Secondary Outcome Measures

  1. New tuberculosis infections [12 weeks]

    The number of participants converting from a negative to a positive latent TB test at follow-up.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • all household contacts of a new case of pulmonary TB (smear, culture or PCR positive) newly diagnosed at each clinic.
Exclusion Criteria:
  • household contacts found to have co-prevalent active TB at enrolment

  • household contacts planning to leave the house at the time of enrolment

  • household contacts of index cases having already initiated TB treatment for > 48h

  • household contacts of index cases that are currently hospitalized

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pontificia Universidad Católica de Chile Santiago Chile

Sponsors and Collaborators

  • Pontificia Universidad Catolica de Chile
  • Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
  • Agencia Nacional de Investigación y Desarrollo, ANID

Investigators

  • Principal Investigator: María Elvira Balcells, MD; MSc, School of Medicine. Pontificia Universidad Católica de Chile.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pontificia Universidad Catolica de Chile
ClinicalTrials.gov Identifier:
NCT04938596
Other Study ID Numbers:
  • 1211225
First Posted:
Jun 24, 2021
Last Update Posted:
Oct 11, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 11, 2021